EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer

Komal L Jhaveri, Seock-Ah Im, Cristina Saura, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Eirini Thanopoulou, Noopur Shankar, Yanling Jin, Thomas J Stout, Tiffany D Clark und 3 weitere

New England Journal of Medicine · 10.07.2025 · 393 (2) · 151-161

DOI: 10.1056/nejmoa2501796 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 10.07.2025. Verfasst von Komal L Jhaveri und 14 weiteren Autor:innen. Beteiligte Einrichtung: Breast and Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Class I Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 134-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Roche, F. Hoffmann–La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClass I Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsBreast Neoplasms, MaleAdultAgedFemaleHumansMiddle AgedDouble-Blind MethodFulvestrantKaplan-Meier EstimateMutationPiperazinesProgression-Free SurvivalPyridinesFollow-Up StudiesTreatment OutcomeMaleImidazolesOxazoles

Substanzen

Class I Phosphatidylinositol 3-KinasesFulvestrantinavolisibpalbociclibPIK3CA protein, humanPiperazinesPyridinesPhosphoinositide-3 Kinase InhibitorsImidazolesOxazoles

Autor:innen und Institutionen

  • Breast and Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
  • Weill Cornell Medical College, New York.
  • Seoul National University Hospital, Seoul National University College of Medicine, Cancer Research Institute, Seoul National University, Seoul, South Korea.
  • Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona.
  • German Breast Group, Neu-Isenburg, Frankfurt, Germany.
  • Center for Hematology and Oncology Bethanien, Goethe University, Frankfurt, Germany.

Förderung

  • NCI NIH HHS
  • Roche
  • F. Hoffmann–La Roche

Zitieren

APA

Jhaveri, K. L., Im, S. A., Saura, C., Loibl, S., Kalinsky, K., Schmid, P., Loi, S., Thanopoulou, E., Shankar, N., Jin, Y., Stout, T. J., Clark, T. D., Song, C., Juric, D., & Turner, N. C. (2025). Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer. New England Journal of Medicine, 393(2), 151-161. https://doi.org/10.1056/nejmoa2501796

Vancouver

Jhaveri KL, Im SA, Saura C, Loibl S, Kalinsky K, Schmid P, et al. Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer. New England Journal of Medicine. 2025;393(2):151-161. doi:10.1056/nejmoa2501796

BibTeX
@article{Jhaveri2025,
  author = {Jhaveri, Komal L and Im, Seock-Ah and Saura, Cristina and Loibl, Sibylle and Kalinsky, Kevin and Schmid, Peter and Loi, Sherene and Thanopoulou, Eirini and Shankar, Noopur and Jin, Yanling and Stout, Thomas J and Clark, Tiffany D and Song, Chunyan and Juric, Dejan and Turner, Nicholas C},
  title = {Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {2},
  pages = {151--161},
  doi = {10.1056/nejmoa2501796}
}
Kostenlos starten →